Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban PK/PD in Bariatric Surgery Patients
NCT06326138Phase 1Withdrawn
- Start
- Mar 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of edoxaban in venous thromboembolism (VTE) (2 arms). Primary endpoint: Pharmacokinetics edoxaban parameter at 24 hours. Planned start Mar 2024; status: withdrawn.
02
Drugs
edoxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06326138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06326138.